Biomarker roles identification of miR-106 family for predicting the risk and poor survival of colorectal cancer

Peng, Qiliang; Shen, Yi; Zhao, Peifeng; Cheng, Ming; Zhu, Yaqun; Xu, Bo

doi:10.1186/s12885-020-06863-9

BMC Cancer

Table 2 The main features of the included studies for miR-106 family in the prognosis of CRC

From: Biomarker roles identification of miR-106 family for predicting the risk and poor survival of colorectal cancer

First author	Year	Country	Ethnicity	M/F	N	Age	TNM stage	Sample source	miRNA	Methods	Endpoints	Follow-up time (months)	Hazard ratio
Diaz et al. [25]	2008	Spain	European	71/39	110	69	I-IV	Tissue	miR-106a	RT-PCR	DFS	68	0.36(0.17–0.77)
Zhang et al. [28]	2013	China	Asian	79/59	138	65	II	Tissue	miR-106b	RT-PCR	DFS	60	2.36(0.93–6.03)
Zhang et al. [28]	2013	China	Asian	86/51	137	65	I-IV	Tissue	miR-106b	RT-PCR	DFS	60	2.15(0.90–5.11)
Zhang et al. [28]	2013	China	Asian	266/194	460	65	I-IV	Tissue	miR-106b	RT-PCR	DFS	60	2.03(1.34–3.06)
Kjersem et al. [29]	2014	Norway	European	82/68	150	61	I-III	Plasma	miR-106a	RT-PCR	DFS	NA	1.13(0.90–1.41)
Bullock et al. [31]	2015	UK	European	38/12	50	74	I-III	Tissue	miR-106a	RT-PCR	DFS	96	2.91(1.32–6.42)
Li et al. [23]	2015	China	Asian	113/62	175	57	II-III	Serum	miR-106a	RT-PCR	DFS	36	3.02(1.36–6.73)
Zhang et al. [34]	2015	China	Asian	54/39	93	60	I-III	Tissue	miR-106b	RT-PCR	DFS	61	3.47(1.13–10.63)
Yue et al. [33]	2015	China	Asian	42/28	70	65	I-IV	Tissue	miR-106a	RT-PCR	DFS	80	2.21(1.46–4.11)
Caritg et al. [35]	2016	Spain	European	43/26	69	67	II	Tissue	miR-106b	RT-PCR	DFS	140	2.25(0.88–5.75)
Hao et al. [8, 36]	2017	China	Asian	92/46	138	56	I-IV	Tissue	miR-106a	RT-PCR	DFS	60	1.22(0.70–2.12)
Diaz et al. [25]	2008	Spain	European	71/39	110	69	I-IV	Tissue	miR-106a	RT-PCR	OS	68	0.53(0.26–1.07)
Schetter et al. [26]	2008	USA	Caucasians	66/18	84	65	I-IV	Tissue	miR-106a	RT-PCR	OS	68	2.40(1.20–5.10)
Bovell et al. [27]	2013	UK	European	188/193	381	65	I-IV	Tissue	miR-106a	RT-PCR	OS	180	1.42(1.01–2.01)
Kjersem et al. [29]	2014	Norway	European	82/68	150	61	I-III	Plasma	miR-106a	RT-PCR	OS	NA	1.17(0.90–1.52)
Ak et al. [30]	2014	Turkey	European	23/17	40	37	I-IV	Tissue	miR-106a	RT-PCR	OS	24	1.46(0.40–5.37)
Bullock et al. [31]	2015	UK	European	38/12	50	74	I-II	Tissue	miR-106a	RT-PCR	OS	96	2.25(1.00–5.04)
Wang et al. [32]	2015	China	Asian	94/89	183	65	I-IV	Tissue	miR-106b	ISH	OS	80	0.83(0.64–1.07)
Yue et al. [33]	2015	China	Asian	42/28	70	65	I-IV	Tissue	miR-106a	RT-PCR	OS	80	2.07(1.22–3.85)
Zhang et al. [34]	2015	China	Asian	54/39	93	60	I-III	Tissue	miR-106b	RT-PCR	OS	61	3.95(1.05–14.80)
Hao et al. [8]	2016	China	Asian	40/25	65	60	I-IV	Tissue	miR-106a	RT-PCR	OS	60	1.40(1.25–1.93)
Hao et al. [36]	2017	China	Asian	92/46	138	56	I-IV	Tissue	miR-106a	RT-PCR	OS	60	1.87 (1.13–3.09)

M male, F female, N number

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com